1 Division of General Internal Medicine, University of Pittsburgh School of Medicine , Pittsburgh, Pennsylvania.
J Womens Health (Larchmt). 2013 Oct;22(10):817-24. doi: 10.1089/jwh.2013.4262. Epub 2013 Aug 9.
We evaluated how computerized clinical decision support (CDS) affects the counseling women receive when primary care physicians (PCPs) prescribe potential teratogens and how this counseling affects women's behavior.
Between October 2008 and April 2010, all women aged 18-50 years visiting one of three community-based family practice clinics or an academic general internal medicine clinic were invited to complete a survey 5-30 days after their clinic visit. Women who received prescriptions were asked if they were counseled about teratogenic risks or contraception and if they used contraception at last intercourse.
Eight hundred one women completed surveys; 27% received a prescription for a potential teratogen. With or without CDS, women prescribed potential teratogens were more likely than women prescribed safer medications to report counseling about teratogenic risks. However, even with CDS 43% of women prescribed potential teratogens reported no counseling. In multivariable models, women were more likely to report counseling if they saw a female PCP (odds ratio: 1.97; 95% confidence interval: 1.26-3.09). Women were least likely to report counseling if they received angiotensin-converting enzyme inhibitors or angiotensin receptor blockers. Women who were pregnant or trying to conceive were not more likely to report counseling. Nonetheless, women who received counseling about contraception or teratogenic risks were more likely to use contraception after being prescribed potential teratogens than women who received no counseling.
Physician counseling can reduce risk of medication-induced birth defects. However, efforts are needed to ensure that PCPs consistently inform women of teratogenic risks and provide access to highly effective contraception.
我们评估了计算机临床决策支持(CDS)如何影响初级保健医生(PCP)开处有潜在致畸风险药物时对女性的咨询,以及这种咨询如何影响女性的行为。
在 2008 年 10 月至 2010 年 4 月期间,邀请所有 18-50 岁的女性在访问三个社区为基础的家庭诊所或一个学术性普通内科诊所后 5-30 天内完成一项调查。收到处方的女性被问到她们是否接受过关于致畸风险或避孕的咨询,以及她们在上一次性交中是否使用了避孕措施。
801 名女性完成了调查;27%的女性收到了潜在致畸药物的处方。无论是否有 CDS,开处潜在致畸药物的女性比开处更安全药物的女性更有可能报告接受了关于致畸风险的咨询。然而,即使有 CDS,仍有 43%的开处潜在致畸药物的女性报告没有接受咨询。在多变量模型中,如果女性看的是女性 PCP(比值比:1.97;95%置信区间:1.26-3.09),她们更有可能报告接受了咨询。如果女性接受了血管紧张素转换酶抑制剂或血管紧张素受体阻滞剂,她们报告咨询的可能性最小。怀孕或试图怀孕的女性不太可能报告接受咨询。尽管如此,接受避孕或致畸风险咨询的女性在被开处潜在致畸药物后更有可能使用避孕措施,而那些没有接受咨询的女性则不然。
医生的咨询可以降低药物引起的出生缺陷的风险。然而,仍需要努力确保 PCP 始终告知女性致畸风险,并提供高效避孕措施。